Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 5/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2264074 | 0.79 | CES1 (0.51) | ADAMTS5CES1TGM2MAOB | |
| SCHEMBL30233871 | 0.74 | ADAMTS5 (0.47) | ADAMTS5CES1PAX8TGM2LRRK2 | |
| SCHEMBL11949353 | 0.73 | CHRM5 (0.39) | CES1BACE1 | |
| SCHEMBL14547270 | 0.72 | POLB (0.39) | ADAMTS5CES1PAX8TGM2LRRK2 | |
| SCHEMBL16381654 | 0.72 | CHRM5 (0.55) | ADAMTS5CES1PAX8TGM2RET | |
| SCHEMBL7612529 | 0.71 | PDK2 (0.52) | — | |
| SCHEMBL2482595 | 0.71 | ADAMTS5 (0.47) | ADAMTS5CES1PAX8TGM2LRRK2 | |
| SCHEMBL2006943 | 0.71 | CYP1A2 (0.61) | ADAMTS5CES1PAX8TGM2LRRK2 | |
| SCHEMBL25012916 | 0.70 | ADAMTS5 (0.40) | ADAMTS5CES1TGM2LRRK2BACE1 | |
| SCHEMBL5480333 | 0.69 | CHRM2 (0.54) | ADAMTS5CES1TGM2LRRK2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354536-B2 | Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1H-3-indazolecarboxylic acid amides | HOFFMAN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8232412-B2 | Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1H-3-indazolecarboxylic acid amides | HOFFMANN-LA ROCHE INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100094011-A1 | DIAZONIUM-FREE METHOD TO MAKE AN INDAZOLE INTERMEDIATE IN THE SYNTHESIS OF BICYCLIC 5-(TRIFLUORMETHOXY)-1H-3-INDAZOLECARBOXYLIC ACID AMIDES | ROCHE CAROLINA INC. | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094011-A1 | DIAZONIUM-FREE METHOD TO MAKE AN INDAZOLE INTERMEDIATE IN THE SYNTHESIS OF BICYCLIC 5-(TRIFLUORMETHOXY)-1H-3-INDAZOLECARBOXYLIC ACID AMIDES | CHRNA7, CHRNA5, CHRNA1 | ADAMTS5 4779/4885CES1 567/4885PAX8 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.